- Home
- VLTO vs RPRX Comparison
VLTO vs RPRX Comparison
Compare VLTO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLTO | RPRX |
|---|---|---|
| Founded | 2023 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 19.5B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VLTO | RPRX |
|---|---|---|
| Price | $89.11 | $49.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $108.90 | $51.40 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 0.61% | ★ 1.90% |
| EPS Growth | ★ 12.57 | N/A |
| EPS | 1.02 | ★ 1.78 |
| Revenue | ★ $5,503,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $8.52 | $38.63 |
| Revenue Next Year | $5.26 | $4.73 |
| P/E Ratio | ★ $22.91 | $27.88 |
| Revenue Growth | ★ 5.97 | 5.06 |
| 52 Week Low | $84.99 | $31.97 |
| 52 Week High | $110.11 | $50.25 |
Technical Indicators
Market Signals| Indicator | VLTO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 60.79 |
| Support Level | $88.40 | $35.34 |
| Resistance Level | $104.02 | $50.08 |
| Average True Range (ATR) | 2.13 | 0.86 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 52.78 | 69.05 |
Price Performance
Historical ComparisonAbout VLTO Veralto Corp
Veralto is a diversified industrial firm organized into two segments: water quality, product quality, and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.5 billion in revenue in 2025.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.